Home / Health / FDA Probes Sevoflurane Safety Amid Rare Neurologic Complications
FDA Probes Sevoflurane Safety Amid Rare Neurologic Complications
3 Jul
Summary
- FDA investigates sevoflurane and other anesthetics' safety.
- Reports link anesthetic exposure to deaths in specific ancestry patients.
- A rare mitochondrial genetic variant may be involved.
The U.S. Food and Drug Administration announced on July 2, 2026, that it is scrutinizing the safety of sevoflurane and other general anesthetics. This investigation stems from reported severe neurologic complications and fatalities among patients of maternal Venezuelan ancestry. These unfortunate events occurred after individuals received routine anesthesia.
Published scientific studies suggest a connection between these adverse outcomes and exposure to sevoflurane, a widely utilized inhaled anesthetic. The FDA also indicated that a rare mitochondrial genetic variant might be a contributing factor in these cases, which have involved both adult and pediatric patients. The agency's probe is ongoing to determine the full extent of the risks.
